Factors associated with cognitive function in patient with Alzheimer's disease with newly prescribed acetylcholinesterase inhibitors: A 1-year retrospective cohort study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patients with Alzheimer's disease on acetylcholinesterase inhibitors may experience cognitive decline if they have a lower BMI or use antipsychotics. Further research is needed to understand these Alzheimer's disease treatment outcomes.
Area Of Science
- Neurology
- Geriatrics
- Pharmacology
Background
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Acetylcholinesterase inhibitors (AChEIs) are a primary treatment for AD symptoms.
- Identifying factors influencing treatment outcomes is crucial for patient management.
Purpose Of The Study
- To investigate predictors of cognitive decline in Alzheimer's disease patients after one year of AChEI treatment.
- To analyze the association between baseline characteristics and 1-year cognitive status.
Main Methods
- Retrospective analysis of electronic medical records from Southern Taiwan (Jan 2015-Sep 2021).
- Inclusion of patients aged ≥60 newly diagnosed with AD and prescribed AChEIs.
- Cognitive assessments (MMSE, CDR) at baseline and 1-year follow-up; logistic regression for analysis.
Main Results
- A total of 1370 patients were analyzed.
- Lower body mass index (BMI) was associated with cognitive decline (AOR: 0.970, P=0.033).
- Higher usage of antipsychotics (AOR: 1.599, P=0.001) and benzodiazepine receptor agonists (AOR: 1.290, P=0.054) correlated with poorer outcomes.
Conclusions
- Lower BMI and concurrent use of antipsychotics or benzodiazepine receptor agonists predict worse cognitive outcomes in AD patients on AChEIs.
- These findings highlight potential risk factors for cognitive progression despite AChEI therapy.
- Clinical attention to BMI and concomitant medications may aid in optimizing AD management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...